107 related articles for article (PubMed ID: 15898348)
21. Pyridorin in type 2 diabetic nephropathy.
Lewis EJ; Greene T; Spitalewiz S; Blumenthal S; Berl T; Hunsicker LG; Pohl MA; Rohde RD; Raz I; Yerushalmy Y; Yagil Y; Herskovits T; Atkins RC; Reutens AT; Packham DK; Lewis JB;
J Am Soc Nephrol; 2012 Jan; 23(1):131-6. PubMed ID: 22034637
[TBL] [Abstract][Full Text] [Related]
22. Rosiglitazone reduces angiotensin II and advanced glycation end product-dependent sustained nuclear factor-kappaB activation in cultured human proximal tubular epithelial cells.
Morcos M; Schlotterer A; Sayed AA; Kukudov G; Oikomonou D; Ibrahim Y; Pfisterer F; Schneider J; Bozorgmehr F; Rudofsky G; Schwenger V; Kientsch-Engels R; Hamann A; Zeier M; Dugi K; Yard B; Humpert PM; van der Woude F; Nawroth PP; Bierhaus A
Horm Metab Res; 2008 Nov; 40(11):752-9. PubMed ID: 18711692
[TBL] [Abstract][Full Text] [Related]
23. [Carbonyl stress inhibitor towards new therapeutic interventions in diabetic nephropathy].
Ishikawa N; Miyata T; Kurokawa K
Nihon Rinsho; 2004 May; 62 Suppl 5():389-92. PubMed ID: 15197951
[No Abstract] [Full Text] [Related]
24. Clinical studies of advanced glycation end product inhibitors and diabetic kidney disease.
Williams ME
Curr Diab Rep; 2004 Dec; 4(6):441-6. PubMed ID: 15539009
[TBL] [Abstract][Full Text] [Related]
25. Adverse renal effects of the AGE inhibitor pyridoxamine in combination with ACEi in non-diabetic adriamycin-induced renal damage in rats.
Waanders F; van Goor H; Navis G
Kidney Blood Press Res; 2008; 31(5):350-9. PubMed ID: 19018148
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of advanced glycation end products: an implicit goal in clinical medicine for the treatment of diabetic nephropathy?
Miyata T; Izuhara Y
Ann N Y Acad Sci; 2008 Apr; 1126():141-6. PubMed ID: 18448808
[TBL] [Abstract][Full Text] [Related]
27. Pyridoxamine, an inhibitor of advanced glycation and lipoxidation reactions: a novel therapy for treatment of diabetic complications.
Metz TO; Alderson NL; Thorpe SR; Baynes JW
Arch Biochem Biophys; 2003 Nov; 419(1):41-9. PubMed ID: 14568007
[TBL] [Abstract][Full Text] [Related]
28. Pyridoxal phosphate prevents progression of diabetic nephropathy.
Nakamura S; Li H; Adijiang A; Pischetsrieder M; Niwa T
Nephrol Dial Transplant; 2007 Aug; 22(8):2165-74. PubMed ID: 17449494
[TBL] [Abstract][Full Text] [Related]
29. Diabetic nephropathy: important pathophysiologic mechanisms.
Soldatos G; Cooper ME
Diabetes Res Clin Pract; 2008 Nov; 82 Suppl 1():S75-9. PubMed ID: 18994672
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway.
Thallas-Bonke V; Thorpe SR; Coughlan MT; Fukami K; Yap FY; Sourris KC; Penfold SA; Bach LA; Cooper ME; Forbes JM
Diabetes; 2008 Feb; 57(2):460-9. PubMed ID: 17959934
[TBL] [Abstract][Full Text] [Related]
31. A new perspective on therapeutic inhibition of advanced glycation in diabetic microvascular complications: common downstream endpoints achieved through disparate therapeutic approaches?
Sourris KC; Harcourt BE; Forbes JM
Am J Nephrol; 2009; 30(4):323-35. PubMed ID: 19556753
[TBL] [Abstract][Full Text] [Related]
32. Preventive Effect of Salicylate and Pyridoxamine on Diabetic Nephropathy.
Abouzed TK; Munesue S; Harashima A; Masuo Y; Kato Y; Khailo K; Yamamoto H; Yamamoto Y
J Diabetes Res; 2016; 2016():1786789. PubMed ID: 28042580
[No Abstract] [Full Text] [Related]
33. Inhibition of advanced glycation end products (AGEs): an implicit goal in clinical medicine for the treatment of diabetic nephropathy?
Miyata T; Dan T
Diabetes Res Clin Pract; 2008 Nov; 82 Suppl 1():S25-9. PubMed ID: 18954918
[TBL] [Abstract][Full Text] [Related]
34. Potential new therapeutic agents for diabetic kidney disease.
Turgut F; Bolton WK
Am J Kidney Dis; 2010 May; 55(5):928-40. PubMed ID: 20138415
[TBL] [Abstract][Full Text] [Related]
35. Advanced glycation end-products induce cell cycle arrest and hypertrophy in podocytes.
Rüster C; Bondeva T; Franke S; Förster M; Wolf G
Nephrol Dial Transplant; 2008 Jul; 23(7):2179-91. PubMed ID: 18344241
[TBL] [Abstract][Full Text] [Related]
36. Effect of protocatechualdehyde on receptor for advanced glycation end products and TGF-beta1 expression in human lens epithelial cells cultured under diabetic conditions and on lens opacity in streptozotocin-diabetic rats.
Kim YS; Kim NH; Lee SW; Lee YM; Jang DS; Kim JS
Eur J Pharmacol; 2007 Aug; 569(3):171-9. PubMed ID: 17597607
[TBL] [Abstract][Full Text] [Related]
37. Effects of pyridoxamine (K-163) on glucose intolerance and obesity in high-fat diet C57BL/6J mice.
Hagiwara S; Gohda T; Tanimoto M; Ito T; Murakoshi M; Ohara I; Yamazaki T; Matsumoto M; Horikoshi S; Funabiki K; Tomino Y
Metabolism; 2009 Jul; 58(7):934-45. PubMed ID: 19427656
[TBL] [Abstract][Full Text] [Related]
38. From molecular footprints of disease to new therapeutic interventions in diabetic nephropathy.
Miyata T; Yamamoto M; Izuhara Y
Ann N Y Acad Sci; 2005 Jun; 1043():740-9. PubMed ID: 16037301
[TBL] [Abstract][Full Text] [Related]
39. Advanced glycation endproducts: what is their relevance to diabetic complications?
Ahmed N; Thornalley PJ
Diabetes Obes Metab; 2007 May; 9(3):233-45. PubMed ID: 17391149
[TBL] [Abstract][Full Text] [Related]
40. Possible participation of advanced glycation end products in the pathogenesis of osteoporosis in diabetic patients.
Yamagishi S; Nakamura K; Inoue H
Med Hypotheses; 2005; 65(6):1013-5. PubMed ID: 16146671
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
